VivoSim Labs Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
11
- Stock Symbol
-
VIVS
- Investments
-
2
- Share Price
-
$0.13
- (As of Friday Closing)
VivoSim Labs General Information
Description
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.
Contact Information
Website
www.vivosim.aiCorporate Office
- 11555 Sorrento Valley Road
- Suite 100
- San Diego, CA 92121
- United States
Corporate Office
- 11555 Sorrento Valley Road
- Suite 100
- San Diego, CA 92121
- United States
VivoSim Labs Stock Performance
As of 13-Nov-2026, VivoSim Labs’s stock price is $0.13. Its current market cap is $2.58M with 20.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.13 | $0.14 | $0.12 - $3.40 | $2.58M | 20.3M | 1M | -$4.47 |
VivoSim Labs Financials Summary
As of 30-Jun-2026, VivoSim Labs has a trailing 12-month revenue of $112K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | (614) | 18 | 3,931 | 6,547 |
| Revenue | 112 | 131 | 144 | 109 |
| EBITDA | (12,346) | (13,881) | (2,350) | (14,794) |
| Net Income | (12,338) | (13,843) | (2,488) | (14,671) |
| Total Assets | 3,847 | 7,386 | 14,650 | 6,349 |
| Total Debt | 316 | 447 | 942 | 1,394 |
VivoSim Labs Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
VivoSim Labs Comparisons
Industry
Financing
Details
VivoSim Labs Competitors (35)
One of VivoSim Labs’s 35 competitors is Aspect Biosystems, a Venture Capital-Backed company based in Vancouver, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aspect Biosystems | Venture Capital-Backed | Vancouver, Canada | ||||
| WaVe Life Sciences | Formerly VC-backed | Cambridge, MA | ||||
| Byondis | Corporation | Nijmegen, Netherlands | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Halozyme Therapeutics | Formerly VC-backed | San Diego, CA |
VivoSim Labs Patents
VivoSim Labs Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3171987-A1 | Crystalline forms of a farnesoid x receptor agonist | Pending | 18-Mar-2020 | ||
| CA-3172205-A1 | Farnesoid x receptor agonists for the treatment of disease | Pending | 18-Mar-2020 | ||
| CA-3112411-A1 | Farnesoid x receptor agonists and uses thereof | Pending | 18-Sep-2018 | ||
| US-20230382913-A1 | Farnesoid x receptor agonists and uses thereof | Inactive | 18-Sep-2018 | ||
| WO-2019227063-A1 | Methods, assays, and kits for evaluating the performance of engineered liver tissue constructs | Inactive | 25-May-2018 | A61B5/15003 |
VivoSim Labs Signals
VivoSim Labs Investments & Acquisitions (2)
VivoSim Labs’s most recent deal was a Corporate Asset Purchase with Organovo (FXR Program and Related Assets in San Ramon, California) for . The deal was made on 10-Mar-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Organovo (FXR Program and Related Assets in San Ramon, California) | 10-Mar-2023 | Corporate Asset Purchase | Buildings and Property | ||
| VivoSim Labs | 08-Feb-2012 | Reverse Merger | Biotechnology |
VivoSim Labs ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
VivoSim Labs Exits (2)
VivoSim Labs’s most recent exit was on 10-Mar-2023 from Organovo (FXR Program and Related Assets in San Ramon, California). The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Organovo (FXR Program and Related Assets in San Ramon, California) | 10-Mar-2023 | Completed |
|
||
| VivoSim Labs | 08-Feb-2012 | Reverse Merger | Completed |
VivoSim Labs FAQs
-
When was VivoSim Labs founded?
VivoSim Labs was founded in 2007.
-
Where is VivoSim Labs headquartered?
VivoSim Labs is headquartered in San Diego, CA.
-
What is the size of VivoSim Labs?
VivoSim Labs has 11 total employees.
-
What industry is VivoSim Labs in?
VivoSim Labs’s primary industry is Biotechnology.
-
Is VivoSim Labs a private or public company?
VivoSim Labs is a Public company.
-
What is VivoSim Labs’s stock symbol?
The ticker symbol for VivoSim Labs is VIVS.
-
What is the current stock price of VivoSim Labs?
As of 13-Nov-2026 the stock price of VivoSim Labs is $0.13.
-
What is the current market cap of VivoSim Labs?
The current market capitalization of VivoSim Labs is $2.58M.
-
What is VivoSim Labs’s current revenue?
The trailing twelve month revenue for VivoSim Labs is $112K.
-
Who are VivoSim Labs’s competitors?
Aspect Biosystems, WaVe Life Sciences, Byondis, CytomX Therapeutics, and Halozyme Therapeutics are some of the 35 competitors of VivoSim Labs.
-
What is VivoSim Labs’s annual earnings per share (EPS)?
VivoSim Labs’s EPS for 12 months was -$4.47.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process